Search research articles
Contact Us
Filters
Showing results (191-200 of 206) with videos related to
Page
of 21
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
Giuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Blood Cancer Journal
|
April 20, 2021
Germline variants at SOHLH2 influence multiple myeloma risk
Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Blood Cancer Journal
|
November 16, 2021
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 22, 2021
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs
Paula Saavedra-García, Monica Roman-Trufero, Hibah A Al-Sadah, et al.
Haematologica
|
June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Toxicology Reports
|
May 14, 2019
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
British Journal of Haematology
|
September 27, 2018
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Martin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Nature Genetics
|
March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
Niels Weinhold, David C Johnson, Daniel Chubb, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 206) with videos related to
Sort By:
Page
of 21
Clinical Lymphoma, Myeloma & Leukemia
|
November 29, 2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
Giuseppe Bertuglia, Elisa Seneca, Timothy Corbett, et al.
Blood Cancer Journal
|
April 20, 2021
Germline variants at SOHLH2 influence multiple myeloma risk
Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Blood Cancer Journal
|
November 16, 2021
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
Laura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 22, 2021
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs
Paula Saavedra-García, Monica Roman-Trufero, Hibah A Al-Sadah, et al.
Haematologica
|
June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Toxicology Reports
|
May 14, 2019
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
British Journal of Haematology
|
September 27, 2018
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Martin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Nature Genetics
|
March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
Niels Weinhold, David C Johnson, Daniel Chubb, et al.
Page
of 21